CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

ANDA207193Orig1s003/011

Name: Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg

Sponsor: Perrigo R&D Company

Approval Date: August 18, 2017

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA207193Orig1s003/011

CONTENTS

Reviews / Information Included in this Review

Approval Letter	**X**
Tentative Approval Letter	
Labeling	**X**
Labeling Review(s)	**X**
Medical Review(s)	
Chemistry Review(s)	
Pharm/Tox Review	
Bioequivalence Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Other Review(s)	
Administrative & Correspondence Documents	

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA207193Orig1s003/011

APPROVAL LETTER

ANDA 207193/S-003 and S-011

CHANGES BEING EFFECTED
APPROVAL

Perrigo R&D Company
515 Eastern Avenue
Allegan, MI 49010
Attention: Derick Winkle
Senior Manager, Regulatory Affairs

Dear Sir:

This is in reference to your supplemental abbreviated new drug applications (sANDAs) received for review on March 22, 2018 (S-003) and April 10, 2019 (S-011), submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (base)(OTC).

These sANDAs, submitted as “Changes Being Effected," provide for:

S-003: Revised insert labeling to be in accordance with the reference listed drug (RLD), Nexium ® 24HR, NDA 204655/S-009, approved on January 24, 2018.

S-011: Revised insert labeling to be in accordance with the RLD, Nexium® 24HR, NDA 204655/S-011, approved on April 4, 2019.

We have completed the review of these supplemental applications. They are approved, effective on the date of this letter. However, please make the following revision to the labeling and submit it in your next Annual Report, provided the change is described in full.

STRUCTURED PRODUCT LABELING (SPL)

Omission of “sugar sphere” or the ingredients of “sugar sphere” from the Inactive Ingredient table is not acceptable. Revise the table to list all inactive ingredients of your drug product. If “sugar sphere” is not available, list each ingredient of the “sugar sphere” separately.

REPORTING REQUIREMENTS

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98 and at section 506I of the FD&C Act. The Office of Generic Drugs should

be advised of any change in the marketing status of this drug or if this drug will not be available for sale after approval. In particular, under section 506I(b) of the FD&C Act, you are required to notify the Office of Generic Drugs in writing within 180 days from the date of this letter if this drug will not be available for sale within 180 days from the date of approval. As part of such written notification, you must include (1) the identity of the drug by established name and proprietary name (if any); (2) the ANDA number; (3) the strength of the drug; (4) the date on which the drug will be available for sale, if known; and (5) the reason for not marketing the drug after approval.

ANNUAL FACILITY FEES

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions [1] with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

Sincerely yours,

{See appended electronic signature page}

For Rachel Goehe, Ph.D.
Director
Division of Labeling Review
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research

[1] Some of these provisions were amended by the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Public Law 115-52, Title III).

Ellen Koo

Digitally signed by Ellen Koo
Date: 1/21/2020 12:43:30PM
GUID: 508da73d0002b687dfbf9b3859d80789

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA207193Orig1s003/011

LABELING

FINAL PRINTED LABELING
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES 20 mg
14 - COUNT BOTTLE CARTON



MODIFIED FORMAT

TYPE SIZES:

TITLE: 8 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
TITLE (continued)**: 7 pt Helvetica Neue LT Std 77 Bold Condensed Oblique**
(continued) **7 pt Helvetica Neue LT Std 57 Condensed**
HEADINGS: 7 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
SUBHEADINGS: 6 pt Helvetica Neue LT Std 77 Bold Condensed
TEXT: 6 pt Helvetica Neue LT Std 57 Condensed
LEADING: 6 and 6.1 pt
BULLETS: 5 pt Square with 2 M'S spacing between statements
TELEPHONE #: 6 pt Helvetica Neue LT Std 77 Bold Condensed
HEAVY LINES: 1.5 pt
HAIRLINES: 0.5 pt
Hairlines extend to within two spaces of the "Drug Facts" box

4-9-19

FINAL PRINTED LABELING
ANDA 207193
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES, 20 mg
MINI CAPSULE
14 - COUNT BOTTLE CARTON



MODIFIED FORMAT

TYPE SIZES:
TITLE: 8 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
TITLE (continued): 7 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
(continued) 7 pt Helvetica Neue LT Std 57 Condensed
HEADINGS: 7 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
SUBHEADINGS: 6 pt Helvetica Neue LT Std 77 Bold Condensed
TEXT: 6 pt Helvetica Neue LT Std 57 Condensed
LEADING: 6 and 6.1 pt
BULLETS: 5 pt Square with 2 M'S spacing between statements
TELEPHONE #: 6 pt Helvetica Neue LT Std 77 Bold Condensed
HEAVY LINES: 1.5 pt
HAIRLINES: 0.5 pt
Hairlines extend to within two spaces of the "Drug Facts" box

4-9-19

FINAL PRINTED LABELING
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES 20 mg
28 - COUNT BOTTLE CARTON



STANDARD FORMAT

TYPE SIZES:
TITLE: 9 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
TITLE (continued): 8 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
(continued) 8 pt Helvetica Neue LT Std 57 Condensed
HEADINGS: 8 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
SUBHEADINGS: 6 pt Helvetica Neue LT Std 77 Bold Condensed
TEXT: 6 pt Helvetica Neue LT Std 57 Condensed
LEADING: 6.5 pt
BULLETS: 5 pt Square with 2 M'S spacing between statements
TELEPHONE #: 6 pt Helvetica Neue LT Std 77 Bold Condensed
HEAVY LINES: 1.5 pt
HAIRLINES: 0.5 pt
Hairlines extend to within two spaces of the "Drug Facts" box

4-9-19

FINAL PRINTED LABELING
ANDA 207193
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES, 20 mg
MINI CAPSULE
28 - COUNT BOTTLE CARTON

KEEP CARTON FOR COMPLETE WARNINGS AND IMPORTANT INFORMATION.

Drug Facts

Active ingredient (in each capsule) — **Purpose**

Esomeprazole 20 mg.....Acid reducer
(Each delayed-release capsule corresponds to 22 mg esomeprazole magnesium dihydrate)

Uses
- treats frequent heartburn (occurs 2 or more days a week)
- not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Warnings
Allergy alert: Do not use if you are allergic to esomeprazole

Do not use if you have:
- trouble or pain swallowing food, vomiting with blood, or bloody or black stools
- heartburn with **lightheadedness, sweating or dizziness**
- chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness
- frequent **chest pain**

These may be signs of a serious condition. See your doctor.

Ask a doctor before use if you have
- had heartburn over 3 months. This may be a sign of a more serious condition.
- frequent wheezing, particularly with heartburn
- unexplained weight loss
- nausea or vomiting
- stomach pain

▶

Drug Facts (continued)

Ask a doctor or pharmacist before use if you are
- taking a prescription drug. Acid reducers may interact with certain prescription drugs.

Stop use and ask a doctor if
- your heartburn continues or worsens
- you need to take this product for more than 14 days
- you need to take more than 1 course of treatment every 4 months
- you get diarrhea
- you develop a rash or joint pain

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Directions
- adults 18 years of age and older
- this product is to be used once a day (every 24 hours), every day for 14 days
- may take 1 to 4 days for full effect

14-Day Course of Treatment
- swallow 1 capsule with a glass of water before eating in the morning
- take every day for 14 days
- do not take more than 1 capsule a day
- swallow whole. Do not crush or chew capsules.
- do not use for more than 14 days unless directed by your doctor

▶

Drug Facts (continued)

Repeated 14-Day Courses (If needed)
- you may repeat a 14-day course every 4 months
- **do not take for more than 14 days or more often than every 4 months unless directed by a doctor**
- children under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.

Other information
- read the directions and warnings before use
- keep the carton. It contains important information.
- store at 20-25°C (68-77°F)

Inactive ingredients
FD&C blue no. 1 aluminum lake, FD&C red no. 3, ferric oxide, gelatin, glyceryl monostearate, hypromellose, magnesium stearate, meglumine, methacrylic acid and ethyl acrylate copolymer dispersion, polyethylene glycol, polysorbate 80, shellac, sodium lauryl sulfate, sugar spheres, talc, titanium dioxide, triethyl citrate

Questions or comments?
1-800-719-9260

Tips for Managing Heartburn
- Avoid foods or drinks that are more likely to cause heartburn, such as rich, spicy, fatty and fried foods, chocolate, caffeine, alcohol and even some acidic fruits and vegetables.
- Eat slowly and do not eat big meals.
- Do not eat late at night or just before bedtime.
- Do not lie flat or bend over soon after eating.
- Raise the head of your bed.
- Wear loose-fitting clothing around your stomach.
- If you are overweight, lose weight.
- If you smoke, quit smoking.

Clinically Proven to
Treat Frequent Heartburn

NDC 0113-9123-02

Perrigo®

DIE CUT WINDOW

DIE CUT WINDOW

See new warning information
Treats Frequent Heartburn

Esomeprazole Magnesium
Delayed-Release Capsules
20 mg/Acid Reducer 24 HOUR

28 CAPSULES

Two 14-day courses of treatment

MINI CAPSULES

May take 1 to 4 days for full effect

Distributed By
Perrigo®
Allegan, MI 49010

0 00000 00000 0

CODE AREA

7U4D6 FA C1

Location for lot number and expiration date

EFB 1918
7U4D6FAC1

2 BOTTLES INSIDE



ACTUAL SIZE

Do Not Use if printed foil seal under cap or band around the center of each capsule is broken or missing.

STANDARD FORMAT

TYPE SIZES:
TITLE: 9 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
TITLE (continued): 8 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
(continued) 8 pt Helvetica Neue LT Std 57 Condensed
HEADINGS: 8 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
SUBHEADINGS: 6 pt Helvetica Neue LT Std 77 Bold Condensed
TEXT: 6 pt Helvetica Neue LT Std 57 Condensed
LEADING: 6.5 pt
BULLETS: 5 pt Square with 2 M'S spacing between statements
TELEPHONE #: 6 pt Helvetica Neue LT Std 77 Bold Condensed
HEAVY LINES: 1.5 pt
HAIRLINES: 0.5 pt
Hairlines extend to within two spaces of the "Drug Facts" box

4-9-19

FINAL PRINTED LABELING
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES 20 mg
42 - COUNT BOTTLE CARTON

EFB 1920
898D7FAC3

KEEP CARTON FOR COMPLETE WARNINGS AND IMPORTANT INFORMATION.

Drug Facts

Active ingredient (in each capsule) **Purpose**
Esomeprazole 20 mg.....Acid reducer
(Each delayed-release capsule corresponds to 22 mg esomeprazole magnesium dihydrate)

Uses
- treats frequent heartburn (occurs **2 or more** days a week)
- not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Warnings
Allergy alert: Do not use if you are allergic to esomeprazole

Do not use if you have:
- trouble or pain swallowing food, vomiting with blood, or bloody or black stools
- heartburn with **lightheadedness, sweating or dizziness**
- chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness
- frequent **chest pain**

These may be signs of a serious condition. See your doctor.

Ask a doctor before use if you have
- had heartburn over 3 months. This may be a sign of a more serious condition.
- frequent wheezing, particularly with heartburn
- unexplained weight loss
- nausea or vomiting - stomach pain

Ask a doctor or pharmacist before use if you are
- taking a prescription drug. Acid reducers may interact with certain prescription drugs. ▶

Drug Facts (continued)

Stop use and ask a doctor if
- your heartburn continues or worsens
- you need to take this product for more than 14 days
- you need to take more than 1 course of treatment every 4 months
- you get diarrhea - you develop a rash or joint pain

If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Directions
- adults 18 years of age and older
- this product is to be used once a day (every 24 hours), every day for 14 days
- may take 1 to 4 days for full effect

14-Day Course of Treatment
- swallow 1 capsule with a glass of water before eating in the morning
- take every day for 14 days
- do not take more than 1 capsule a day
- swallow whole. Do not crush or chew capsules.
- do not use for more than 14 days unless directed by your doctor

Repeated 14-Day Courses (if needed)
- you may repeat a 14-day course every 4 months
- **do not take for more than 14 days or more often than every 4 months unless directed by a doctor**
- children under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.

Other information
- read the directions and warnings before use
- keep the carton. It contains important information.
- store at 20-25°C (68-77°F) ▶

Drug Facts (continued)

Inactive ingredients
FD&C blue no. 1, FD&C red no. 3, ferric oxide, gelatin, glyceryl monostearate, hypromellose, magnesium stearate, meglumine, methacrylic acid and ethyl acrylate copolymer dispersion, polyethylene glycol, polysorbate 80, shellac, sodium lauryl sulfate, sugar spheres, talc, titanium dioxide, triethyl citrate

Questions or comments?
1-800-719-9260

Tips for Managing Heartburn
- Avoid foods or drinks that are more likely to cause heartburn, such as rich, spicy, fatty and fried foods, chocolate, caffeine, alcohol and even some acidic fruits and vegetables.
- Eat slowly and do not eat big meals.
- Do not eat late at night or just before bedtime.
- Do not lie flat or bend over soon after eating.
- Raise the head of your bed.
- Wear loose-fitting clothing around your stomach.
- If you are overweight, lose weight.
- If you smoke, quit smoking.

Clinically Proven to
Treat Frequent Heartburn

NDC 0113-9898-03

Perrigo®

DIE CUT WINDOW | DIE CUT WINDOW | DIE CUT WINDOW

See new warning information

Treats Frequent Heartburn

Esomeprazole Magnesium

Delayed-Release Capsules 20 mg/Acid Reducer

24 HOUR

42 CAPSULES

Three 14-day courses of treatment

CAPSULES

May take 1 to 4 days for full effect

Distributed By
Perrigo®
Allegan, MI 49010

0 00000 00000 0

CODE AREA

898D7 FA C3

3 BOTTLES INSIDE

ACTUAL SIZE

Do Not Use if printed foil seal under cap or band around the center of each capsule is broken or missing.

Location for lot number and expiration date

STANDARD FORMAT

TYPE SIZES:
TITLE: 9 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
TITLE (continued): 8 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
(continued) 8 pt Helvetica Neue LT Std 57 Condensed
HEADINGS: 8 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
SUBHEADINGS: 6 pt Helvetica Neue LT Std 77 Bold Condensed
TEXT: 6 pt Helvetica Neue LT Std 57 Condensed
LEADING: 6.5 pt
BULLETS: 5 pt Square with 2 M'S spacing between statements
TELEPHONE #: 6 pt Helvetica Neue LT Std 77 Bold Condensed
HEAVY LINES: 1.5 pt
HAIRLINES: 0.5 pt
Hairlines extend to within two spaces of the "Drug Facts" box

4-9-19

FINAL PRINTED LABELING
ANDA 207193
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES, 20 mg
MINI CAPSULE
42 - COUNT BOTTLE CARTON

EFB 1920
7U4D7FAC1

KEEP CARTON FOR COMPLETE WARNINGS AND IMPORTANT INFORMATION.

Drug Facts

Active ingredient (in each capsule) **Purpose**
Esomeprazole 20 mg.....Acid reducer
(Each delayed-release capsule corresponds to 22 mg esomeprazole magnesium dihydrate)

Uses
- treats frequent heartburn (occurs **2 or more** days a week)
- not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Warnings
Allergy alert: Do not use if you are allergic to esomeprazole

Do not use if you have:
- trouble or pain swallowing food, vomiting with blood, or bloody or black stools
- heartburn with **lightheadedness, sweating or dizziness**
- chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness
- frequent **chest pain**

These may be signs of a serious condition. See your doctor.

Ask a doctor before use if you have
- had heartburn over 3 months. This may be a sign of a more serious condition.
- frequent wheezing, particularly with heartburn
- unexplained weight loss
- nausea or vomiting - stomach pain

Ask a doctor or pharmacist before use if you are
- taking a prescription drug. Acid reducers may interact with certain prescription drugs.

Drug Facts (continued)

Stop use and ask a doctor if
- your heartburn continues or worsens
- you need to take this product for more than 14 days
- you need to take more than 1 course of treatment every 4 months
- you get diarrhea - you develop a rash or joint pain

If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Directions
- adults 18 years of age and older
- this product is to be used once a day (every 24 hours), every day for 14 days
- may take 1 to 4 days for full effect

14-Day Course of Treatment
- swallow 1 capsule with a glass of water before eating in the morning
- take every day for 14 days
- do not take more than 1 capsule a day
- swallow whole. Do not crush or chew capsules.
- do not use for more than 14 days unless directed by a doctor

Repeated 14-Day Courses (if needed)
- you may repeat a 14-day course every 4 months
- **do not take for more than 14 days or more often than every 4 months unless directed by a doctor**

- children under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.

Other information
- read the directions and warnings before use
- keep the carton. It contains important information.
- store at 20-25°C (68-77°F)

Drug Facts (continued)

Inactive ingredients FD&C blue no. 1, FD&C blue no. 1 aluminum lake, FD&C red no. 3, ferric oxide, gelatin, glyceryl monostearate, hypromellose, magnesium stearate, meglumine, methacrylic acid and ethyl acrylate copolymer dispersion, polyethylene glycol, polysorbate 80, shellac, sodium lauryl sulfate, sugar spheres, talc, titanium dioxide, triethyl citrate

Questions or comments?
1-800-719-9260

Tips for Managing Heartburn
- Avoid foods or drinks that are more likely to cause heartburn, such as rich, spicy, fatty and fried foods, chocolate, caffeine, alcohol and even some acidic fruits and vegetables.
- Eat slowly and do not eat big meals.
- Do not eat late at night or just before bedtime.
- Do not lie flat or bend over soon after eating.
- Raise the head of your bed.
- Wear loose-fitting clothing around your stomach.
- If you are overweight, lose weight.
- If you smoke, quit smoking.

Clinically Proven to
Treat Frequent Heartburn

NDC 0113-9123-03

Perrigo®

DIE CUT WINDOW | DIE CUT WINDOW | DIE CUT WINDOW

See new warning information

Treats Frequent Heartburn

Esomeprazole Magnesium
Delayed-Release Capsules 20 mg/Acid Reducer
24 HOUR

42 CAPSULES
Three 14-day courses of treatment

MINI CAPSULES
May take 1 to 4 days for full effect

Distributed By
Perrigo®
Allegan, MI 49010

0 00000 00000 0

CODE AREA

7U4D7 FA C1

3 BOTTLES INSIDE

ACTUAL SIZE

Do Not Use if printed foil seal under cap or band around the center of each capsule is broken or missing.

Location for lot number and expiration date

STANDARD FORMAT

TYPE SIZES:
TITLE: 9 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
TITLE (continued): 8 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
(continued) 8 pt Helvetica Neue LT Std 57 Condensed
HEADINGS: 8 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
SUBHEADINGS: 6 pt Helvetica Neue LT Std 77 Bold Condensed
TEXT: 6 pt Helvetica Neue LT Std 57 Condensed
LEADING: 6.5 pt
BULLETS: 5 pt Square with 2 M'S spacing between statements
TELEPHONE #: 6 pt Helvetica Neue LT Std 77 Bold Condensed
HEAVY LINES: 1.5 pt
HAIRLINES: 0.5 pt
Hairlines extend to within two spaces of the "Drug Facts" box

4-9-19

FINAL PRINTED LABELING
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES 20 mg
14 - COUNT BOTTLE LABEL

898D5FAF2 **ELE 697**

KEEP CARTON FOR COMPLETE WARNINGS AND IMPORTANT INFORMATION.

PEEL BACK HERE

Perrigo®

Treats Frequent Heartburn

Esomeprazole Magnesium Delayed-Release Capsules

20 mg/Acid Reducer

24 HOUR

May take 1 to 4 days for full effect

CAPSULES

14 CAPSULES One 14-day course of treatment

Do Not Use if printed foil seal under cap or band around the center of each capsule is broken or missing.

Distributed By Perrigo
Allegan, MI 49010

CODE AREA

: 898D5 FA F2

Location for lot number and expiration date

TOP PLY

HINGE AREA NO COPY NO VARNISH

Stop use and ask a doctor if ■ your heartburn continues or worsens ■ you need to take this product for more than 14 days ■ you need to take more than 1 course of treatment every 4 months ■ you get diarrhea ■ you develop a rash or joint pain
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
Directions ■ adults 18 years of age and older ■ this product is to be used once a day (every 24 hours), every day for 14 days ■ may take 1 to 4 days for full effect
14-Day Course of Treatment ■ swa low 1 capsule with a glass of water before eating in the morning ■ take every day for 14 days ■ do not take more than 1 capsule a day ■ swallow whole. Do not crush or chew capsules. ■ do not use for more than 14 days unless directed by your doctor
Repeated 14-Day Courses (if needed) ■ you may repeat a 14-day course every 4 months ■ **do not take for more than 14 days or more often than every 4 months unless directed by a doctor** ■ ch ldren under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.
Other information ■ read the directions and warnings before use ■ keep the carton. It contains important information. ■ store at 20-25°C (68-77°F)
Questions or comments? 1-800-719-9260

REVERSE SIDE OF TOP PLY (POB)

Active ingredient (in each capsule) ***Purpose***
Esomeprazole 20 mg ..... Acid reducer
(Each delayed-release capsule corresponds to 22 mg esomeprazole magnesium dihydrate)
Uses ■ treats frequent heartburn (occurs 2 or more days a week) ■ not intended for immediate re ief of heartburn; this drug may take 1 to 4 days for full effect
Warnings
Allergy alert: Do not use if you are allergic to esomeprazole
Do not use if you have: ■ trouble or pain swallowing food, vomiting with blood, or bloody or black stools ■ heartburn with lightheadedness, sweating or dizziness ■ chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness ■ frequent chest pain. These may be signs of a serious condition. See your doctor.
Ask a doctor before use if you have ■ had heartburn over 3 months. This may be a sign of a more serious cond tion. ■ frequent wheezing, particularly with heartburn ■ unexplained weight loss ■ nausea or vomiting ■ stomach pain
Ask a doctor or pharmacist before use if you are ■ taking a prescription drug. Acid reducers may interact w th certain prescription drugs.

▶

ADHESIVE AREA NO COPY

BASE PLY (2-PLY)

NON-DFL FORMAT

TYPE SIZES:
HEADINGS: 4.5 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
SUBHEADINGS: 4.5 pt Helvetica Neue LT Std 77 Bold Condensed
TEXT: 4.5 pt Helvetica Neue LT Std 57 Condensed
LEADING: 4.8 pt
BULLETS: 3.5 pt Square with 5 spaces between statements
TELEPHONE #: 4.5 pt Helvetica Neue LT Std 77 Bold Condensed
LINE: 0.5 pt

4-9-19

FINAL PRINTED LABELING
ANDA 207193
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES, 20 mg
MINI CAPSULE
14 - COUNT BOTTLE LABEL

7U4D5FAF1 **ELE 697**

KEEP CARTON FOR COMPLETE WARNINGS AND IMPORTANT INFORMATION.

PEEL BACK HERE

Perrigo®

Treats Frequent Heartburn

Esomeprazole Magnesium Delayed-Release Capsules

20 mg/Acid Reducer **24 HOUR**

May take 1 to 4 days for full effect

MINI CAPSULES

14 CAPSULES One 14-day course of treatment

Do Not Use if printed foil seal under cap or band around the center of each capsule is broken or missing.

Distributed By Perrigo
Allegan, MI 49010

CODE AREA

: 7U4D5 FA F1

Location for lot number and expiration date

TOP PLY

HINGE AREA NO COPY NO VARNISH

Stop use and ask a doctor if ■ your heartburn continues or worsens ■ you need to take this product for more than 14 days ■ you need to take more than 1 course of treatment every 4 months ■ you get diarrhea ■ you develop a rash or joint pain
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
Directions ■ adults 18 years of age and older ■ this product is to be used once a day (every 24 hours), every day for 14 days ■ may take 1 to 4 days for full effect
14-Day Course of Treatment ■ swa low 1 capsule with a glass of water before eating in the morning ■ take every day for 14 days ■ do not take more than 1 capsule a day ■ swallow whole. Do not crush or chew capsules. ■ do not use for more than 14 days unless directed by your doctor
Repeated 14-Day Courses (if needed) ■ you may repeat a 14-day course every 4 months ■ do not take for more than 14 days or more often than every 4 months unless directed by a doctor ■ ch ldren under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.
Other information ■ read the directions and warnings before use ■ keep the carton. It contains important information. ■ store at 20-25°C (68-77°F)
Questions or comments? 1-800-719-9260

REVERSE SIDE OF TOP PLY (POB)

Active ingredient (in each capsule) *Purpose*
Esomeprazole 20 mg..... Acid reducer
(Each delayed-release capsule corresponds to 22 mg esomeprazole magnesium dihydrate)
Uses ■ treats frequent heartburn (occurs 2 or more days a week) ■ not intended for immediate re ief of heartburn; this drug may take 1 to 4 days for full effect
Warnings
Allergy alert: Do not use if you are allergic to esomeprazole
Do not use if you have: ■ trouble or pain swallowing food, vomiting with blood, or bloody or black stools ■ heartburn with lightheadedness, sweating or dizziness ■ chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness ■ frequent chest pain. These may be signs of a serious condition. See your doctor.
Ask a doctor before use if you have ■ had heartburn over 3 months. This may be a sign of a more serious cond tion. ■ frequent wheezing, particularly with heartburn ■ unexplained weight loss ■ nausea or vomiting ■ stomach pain
Ask a doctor or pharmacist before use if you are ■ taking a prescription drug. Acid reducers may interact w th certain prescription drugs.

▶

ADHESIVE AREA NO COPY

BASE PLY (2-PLY)

NON-DFL FORMAT

TYPE SIZES:

HEADINGS: 4.5 pt Helvetica Neue LT Std 77 Bold Condensed Oblique
SUBHEADINGS: 4.5 pt Helvetica Neue LT Std 77 Bold Condensed
TEXT: 4.5 pt Helvetica Neue LT Std 57 Condensed
LEADING: 4.8 and 5 pt
BULLETS: 3.5 pt Square with 5 spaces between statements
TELEPHONE #: 4.5 pt Helvetica Neue LT Std 77 Bold Condensed
LINE: 0.5 pt

4-9-19

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA207193Orig1s003/011

LABELING REVIEWS

***** This document contains proprietary information that cannot be released to the public***v.41**

SUPPLEMENT LABELING REVIEW

Division of Labeling Review
Office of Regulatory Operations
Office of Generic Drugs (OGD)
Center for Drug Evaluation and Research (CDER)

Date of this Review	December 18, 2020
Review Cycle Number	1
ANDA(s) and Supplement Number(s)	207193/S-003 and S-011
Applicant Name	Perrigo R&D Company
Proprietary Name, Established Name, and Strength(s) [Add "(OTC)" after strength if applicable]	Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (base) (OTC)
Current Received Date	March 22, 2018 (S-003) and April 10, 2019 (S-011)
Previous Received Date(s) of Proposed Supplement	N/A
Primary Labeling Reviewer	Sarah Nguyen
Secondary Labeling Reviewer	Ellen Koo

Review Conclusion

☐ ACCEPTABLE - No Comments.

☒ ACCEPTABLE - Include Post approval comments.

☐ Minor Deficiency* – Refer to Labeling Deficiencies and Comments for Letter to Applicant

☐ Major Deficiency† – Refer to Labeling Deficiencies and Comments for Letter to Applicant

†Theme - Choose an item.

Justification for Major Deficiency - Choose an item.

*Please Note: The Regulatory Project Manager (RPM) may change the recommendation from Minor Deficiency to Discipline Review Letter/Information Request (DRL/IR) if all other OGD reviews are acceptable. Otherwise, the labeling minor and major deficiencies will be included in the Complete Response Letter (CRL) letter to the applicant.

On Policy Alert List ☐ Yes ☒ No

Acceptable for Filing	☐ Yes	☐ No
Combined Insert/Outsert	☐ Yes	☒ No (If yes, indicate ANDA number)

☒ **For labeling supplement(s):**

These Changes Being Effected supplemental abbreviated new drug applications provide for:

S-003: Revised insert labeling to be in accordance with the reference listed drug (RLD), Nexium ® 24HR, NDA 204655/S-009, approved on January 24, 2018.
S-011: Revised insert labeling to be in accordance with the reference listed drug (RLD), Nexium® 24HR, NDA 204655/S-011, approved on April 4, 2019.

We have completed the review of these supplemental applications. They are approved, effective on the date of this letter. However, please make the following revision to the labeling and submit it in your next Annual Report, provided the change is described in full.

STRUCTURED PRODUCT LABELING (SPL)

Omission of “sugar sphere” or the ingredients of “sugar sphere” from the Inactive Ingredient table is not acceptable. Revise the table to list all inactive ingredients of your drug product. If “sugar sphere” is not available, list each ingredient of the “sugar sphere” separately.

Contents

1. ANDA REGULATORY INFORMATION:

Type of Supplement: CBE	
Are there any pending issues in DLR's SharePoint Drug Facts? If Yes, please explain:	**NO**
Is the drug product listed in the Policy Alert Tracker on DLRS SharePoint? If Yes, please explain:	**NO**
Is the drug product listed on the Susceptibility Test Interpretive Criteria web page? **https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm575163.htm**	NO
Reason for Submission: S-003: Revised insert labeling to be in accordance with the reference listed drug (RLD), Nexium ® 24HR, NDA 204655/S-009, approved on January 24, 2018. S-011: Revised insert labeling to be in accordance with the reference listed drug (RLD), Nexium® 24HR, NDA 204655/S-011, approved on April 4, 2019.	
Is this supplement combined with another discipline?	**NO**
Is this product an OTC product?	**YES**
Is this ANDA the RLD?	**NO**

2. MATERIAL ANALYSIS

The results for each material reviewed in this section provide the basis for the labeling comments to the Applicant and other review disciplines.

2.1 MATERIALS REVIEWED

Tables 1 and 2 provide a summary of recommendations for each material analyzed in this review.

Table 1: Review Summary of Container Label and Carton Labeling				
	Final or Draft or NA	**Packaging Sizes**	**Submission Received Date**	**Recommendation**
Container	Final	14 count 14 count, mini	4/10/19	Satisfactory
Blister	N/A	Click here to enter text.	Click here to enter text.	Click here to enter text.
Carton	Final	14, 28, 42 count 14, 28, 42, count, mini	4/10/19	Satisfactory
(Other – specify)	N/A	Click here to enter text.	Click here to enter text.	Click here to enter text.
Table 2 Review Summary of Prescribing Information and Patient Labeling				
	Final or Draft or NA	**Revision Date and/or Code**	**Submission Received Date**	**Recommendation**
Prescribing Information	Click here to enter text.	Click here to enter text.	Click here to enter text.	Click here to enter text.
Medication Guide	Click here to enter	Click here to enter text.	Click here to enter	Click here to enter

	text.		text.	text.
Patient Information	Click here to enter text.	Click here to enter text.	Click here to enter text.	Click here to enter text.
SPL Data Elements	N/A	1 in 1 carton 14 in 1 bottle 2 in 1 carton 14 in one bottle 3 in 1 carton 14 in one bottle	4/10/19	Satisfactory

2.2 MODEL LABELING

The review model labels and labeling used for comparison to the submitted ANDA labeling are described in Table 3.

Table 3: Review Model Labeling for Prescribing Information, Patient Labeling, and Drug Facts Labeling (OTC) (Check the box used as the Model Labeling)

☒ **MOST RECENTLY APPROVED NDA MODEL LABELING**

(If NDA is listed in the discontinued section of the Orange Book, indicate whether the application has been withdrawn and if so, enter the most recently approved ANDA labeling information as applicable.)

NDA#/Supplement# (S-000 if original): NDA 204655/S-011

Supplement Approval Date: April 4, 2019

Proprietary Name: Nexium® 24HR

Established Name: Esomeprazole Magnesium Delayed-Release Capsule

Description of Supplement: Provides for the inclusion of the following drug-drug interaction warning, "Ask a doctor or pharmacist before use if you are taking a prescription drug. Acid reducers may interact with certain prescription drugs."

☐ **MOST RECENTLY APPROVED ANDA MODEL LABELING**

ANDA#/Supplement# (S-000 if original): Click here to enter text.

Supplement Approval Date: Click here to enter text.

Proprietary Name: Click here to enter text.

Established Name: Click here to enter text.

Description of Supplement: Click here to enter text.

☐ **TEMPLATE (e.g., BPCA, PREA, Carve-out):** Click here to enter text.

☐ **OTHER (Describe):** Click here to enter text.

Reviewer Assessment:

Is the NDA listed in the discontinued section of the Orange Book? **NO**
If yes, then comment below regarding the current model labeling.

Comment: No further comments.

2.3 PATENTS AND EXCLUSIVITIES

The Orange Book was searched on 12/18/2019.

Are there any remaining unexpired patents or marketing exclusivities for Model Labeling? **NO**

If YES go to the Table 4 and assessments below.

Table 4 describes how the applicant certified to the Orange Book patent(s) for the Model Labeling (NDA 204655) and how this certification impacts the ANDA labels and labeling. For applications that have no patents

N/A is entered in the patent number column.

Table 4: Impact of Model Labeling Patents on ANDA Labeling					
Patent Number	**Patent Expiration**	**Patent Use Code**	**Patent Use Code Definition**	**Patent Certification**	**Labeling Impact ("Carve-out" or "None" or "Not addressed by firm")**
6,428,810	05/03/2020	U-1509 U-1874	U-1509: Treatment of frequent heartburn by administering a gastric acid reducer U-1874: Treatment of frequent heartburn by administering omeprazole according to claims 1-8	PIV	None

Table 5 describes how the expiration of the Orange Book exclusivities for the Model Labeling impacts the ANDA labels and labeling. For applications that have no exclusivities N/A is entered in the Exclusivity Code column.

Table 5: Impact of Model Labeling Exclusivities on ANDA Labels and Labeling				
Exclusivity Code	**Exclusivity Expiration**	**Exclusivity Code Definition**	**Exclusivity Statement**	**Labeling Impact ("Carve-out" or "None" or "Not addressed by firm")**
N/A				

Reviewer Assessment:

Are there any recently expired patents or exclusivities? **NO**
If yes, did these patents or exclusivities have any labeling impact? **NO**

Comment: No further comments

2.4 UNITED STATES PHARMACOPEIA (USP) & PHARMACOPEIA FORUM (PF)

The USP was searched on 12/18/2019.

Table 6: USP				
	YES or NO	**Date**	**Monograph Title (NA if no monograph)**	**Packaging and Storage/Labeling Statements (NA if no monograph)**
Currently Official	Yes		Esomeprazole Magnesium Delayed-Release Capsules	•Packaging and Storage: Preserve in tight containers. Store at room temperature. •Labeling: (b) (4)
Not Yet Official	No	Click here to enter the date when the monograph becomes official.	NA	NA

Reviewer Assessment:

Are the required USP recommendations and/or differences in test methods (e.g., dissolution, organic impurities, assay) reflected in the labels/labeling? **YES**

Comment: Dissolution was found acceptable on 6/26/18.

2.5 HISTORY OF ANDA

We evaluated previously approved and pending supplements (Table 7) to determine if actions are needed for the current review.

Table 7: Labeling History of ANDA		
Original or Supplement	**Approval Date**	**What post approval changes were requested and were the changes addressed?**
Original	8/18/17	STRUCTURED PRODUCT LABELING (SPL) Omission of "sugar sphere" or the ingredients of "sugar sphere" from the Inactive Ingredient table is not acceptable. Revise the table to list all inactive ingredients of your drug product. If "sugar sphere" is not available, list each ingredient of the "sugar sphere" separately. This was not addressed, and we will include as part of our comments to the applicant.
Are there any Pending Labeling Supplements for this ANDA that impact labeling? NO		
Pending Supplement	**Submission Date**	**Labeling Impact**

3. ASSESSMENT OF CURRENT SUPPLEMENT'S LABELING

3.1 CONTAINER AND CARTON LABELS

Reviewer Assessment:

Were container or carton labels submitted in this supplement? **YES**
If yes, state the reason for the submission, and comment below whether the proposed revisions are acceptable or deficient.

Comment: Applicant has satisfactorily updated their carton and container labels to be in line with the RLD, NDA 204655/S-011, approved on April 4, 2019, which provides for the inclusion of the following drug-drug interaction warning, "Ask a doctor or pharmacist before use if you are taking a prescription drug. Acid reducers may interact with certain prescription drugs."

3.1.1 MODEL CONTAINER LABELS

Please provide the reference listed drug labels if applicant submits container, blister, carton, etc.

Model container/carton/blister labels [Source: NDA 204655/S-011, approved 4/4/19]

Stop use and ask a doctor if ■ your heartburn continues or worsens ■ you need to take this product for more than 14 days ■ you need to take more than 1 course of treatment every 4 months ■ you get diarrhea ■ you develop a rash or joint pain

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Directions ■ adults 18 years of age and older ■ this product is to be used once a day (every 24 hours), every day for 14 days ■ may take 1 to 4 days for full effect

14-Day Course of Treatment ■ swallow 1 capsule with a glass of water before eating in the morning ■ take every day for 14 days ■ do not take more than 1 capsule a day ■ swallow whole. Do not crush or chew capsules. ■ do not use for more than 14 days unless directed by your doctor

Repeated 14-Day Courses (If needed) ■ you may repeat a 14-day course every 4 months ■ **do not take for more than 14 days or more often than every 4 months unless directed by a doctor** ■ children under 18 years of age: ask a doctor before use.

Heartburn in children may sometimes be caused by a serious condition.

Other information ■ read the directions and warnings before use ■ keep the carton. It contains important information. ■ store at 20-25°C (68-77°F)

Questions or comments? call toll-free weekdays 9 AM to 5 PM EST at 1-866-226-1600

Active Ingredient (in each capsule) ***Purpose***

Esomeprazole 20 mg ..... Acid reducer

(Each delayed-release capsule corresponds to 22.3 mg esomeprazole magnesium trihydrate)

Uses ■ treats frequent heartburn (occurs 2 or more days a week) ■ not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Warnings

Allergy alert: Do not use if you are allergic to esomeprazole

Do not use if you have: ■ trouble or pain swallowing food, vomiting with blood, or bloody or black stools ■ heartburn with lightheadedness, sweating or dizziness ■ chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness ■ frequent chest pain. These may be signs of a serious condition. See your doctor.

Ask a doctor before use if you have ■ had heartburn over 3 months. This may be a sign of a more serious condition ■ frequent wheezing, particularly with heartburn ■ unexplained weight loss ■ nausea or vomiting ■ stomach pain

Ask a doctor or pharmacist before use if you are ■ taking a prescription drug. Acid reducers may interact with certain prescription drugs


KEEP CARTON FOR COMPLETE WARNINGS AND IMPORTANT INFORMATION.
Drug Facts
Active ingredient (in each capsule) Purpose
Esomeprazole 20 mg ..... Acid reducer
(Each delayed-release capsule corresponds to 22.3 mg esomeprazole magnesium trihydrate)
Uses
■ treats frequent heartburn (occurs 2 or more days a week)
■ not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect
Warnings
Allergy alert: Do not use if you are allergic to esomeprazole
Do not use if you have:
■ trouble or pain swallowing food, vomiting with blood, or bloody or black stools
■ heartburn with lightheadedness, sweating or dizziness
■ chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness
■ frequent chest pain
These may be signs of a serious condition. See your doctor.
Ask a doctor before use if you have
■ had heartburn over 3 months. This may be a sign of a more serious condition.
■ frequent wheezing, particularly with heartburn
■ unexplained weight loss
■ nausea or vomiting ■ stomach pain
Ask a doctor or pharmacist before use if you are
■ taking a prescription drug. Acid reducers may interact with certain prescription drugs.
Stop use and ask a doctor if
■ your heartburn continues or worsens
■ you need to take this product for more than 14 days
■ you need to take more than 1 course of treatment every 4 months
■ you get diarrhea
■ you develop a rash or joint pain
Drug Facts (continued)
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
Directions ■ adults 18 years of age and older
■ this product is to be used once a day (every 24 hours), every day for 14 days
■ may take 1 to 4 days for full effect
14-Day Course of Treatment
■ swallow 1 capsule with a glass of water before eating in the morning
■ take every day for 14 days
■ do not take more than 1 capsule a day
■ swallow whole. Do not crush or chew capsules.
■ do not use for more than 14 days unless directed by your doctor
Repeated 14-Day Courses (if needed)
■ you may repeat a 14-day course every 4 months
■ do not take for more than 14 days or more often than every 4 months unless directed by a doctor
■ children under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.
Other Information
■ read the directions and warnings before use
■ keep the carton. It contains important information.
■ store at 20-25°C (68-77°F)
Inactive ingredients carmine, corn starch, FD&C blue no. 2, FD&C blue no. 2 aluminum lake, FD&C red no. 3, FD&C red no. 40, ferric oxide, gelatin, glyceryl monostearate, hydroxypropyl cellulose, hypromellose, magnesium stearate, methacrylic acid copolymer, pharmaceutical ink, polysorbate 80, sucrose, talc, titanium dioxide, triethyl citrate
Questions or comments? call toll-free weekdays 9 AM to 5 PM EST at 1-866-226-1680
Nexium 24HR
Clinically Proven to Treat Frequent Heartburn
Clear Minis
Tips for Managing Heartburn
• Avoid foods or drinks that are more likely to cause heartburn, such as rich, spicy, fatty and fried foods, chocolate, caffeine, alcohol and even some acidic fruits and vegetables.
• Eat slowly and do not eat big meals.
• Do not eat late at night or just before bedtime.
• Do not lie flat or bend over soon after eating.
• Raise the head of your bed.
• Wear loose-fitting clothing around your stomach.
• If you are overweight, lose weight.
• If you smoke, quit smoking.
See new warning information
NDC 0573-2452-14
Treats Frequent Heartburn
Nexium esomeprazole magnesium delayed-release capsules 20 mg/acid reducer 24HR
Nexium esomeprazole magnesium delayed-release capsules 20 mg/acid reducer 24HR
Marketed by:
Pfizer, Madison, NJ 07940 USA
© 2019 Pfizer Inc.
Made in France
For most recent product information, visit www.Nexium24HR.com
Nexium is a registered trademark of Astra/zeneca AB and is used under license.
Clear Minis
May take 1 to 4 days for full effect
14 CAPSULES
One 14-day course of treatment
1 BOTTLE INSIDE
Treats Frequent Heartburn
Nexium 24HR
14 Capsules Clear Minis
ACTUAL SIZE
Do Not Use if seal under bottle cap imprinted with "SEALED for YOUR PROTECTION" or yellow band around the center of each capsule is broken or missing.


KEEP CARTON FOR COMPLETE WARNINGS AND IMPORTANT INFORMATION.
Drug Facts
Active ingredient (in each capsule) Purpose
Esomeprazole 20 mg ..... Acid reducer
(Each delayed-release capsule corresponds to 22.3 mg esomeprazole magnesium trihydrate)
Uses
■ treats frequent heartburn (occurs 2 or more days a week)
■ not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect
Warnings
Allergy alert: Do not use if you are allergic to esomeprazole
Do not use if you have:
■ trouble or pain swallowing food, vomiting with blood, or bloody or black stools
■ heartburn with lightheadedness, sweating or dizziness
■ chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness
■ frequent chest pain
These may be signs of a serious condition. See your doctor.
Ask a doctor before use if you have
■ had heartburn over 3 months. This may be a sign of a more serious condition.
■ frequent wheezing, particularly with heartburn
■ unexplained weight loss
■ nausea or vomiting ■ stomach pain
Ask a doctor or pharmacist before use if you are
■ taking a prescription drug. Acid reducers may interact with certain prescription drugs.
Stop use and ask a doctor if
■ your heartburn continues or worsens
■ you need to take this product for more than 14 days
■ you need to take more than 1 course of treatment every 4 months
■ you get diarrhea
■ you develop a rash or joint pain
Drug Facts (continued)
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
Directions
■ adults 18 years of age and older
■ this product is to be used once a day (every 24 hours), every day for 14 days
■ may take 1 to 4 days for full effect
14-Day Course of Treatment
■ swallow 1 capsule with a glass of water before eating in the morning
■ take every day for 14 days
■ do not take more than 1 capsule a day
■ swallow whole. Do not crush or chew capsules.
■ do not use for more than 14 days unless directed by your doctor
Repeated 14-Day Courses (if needed)
■ you may repeat a 14-day course every 4 months
■ do not take for more than 14 days or more often than every 4 months unless directed by a doctor
■ children under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.
Other Information
■ read the directions and warnings before use
■ keep the carton. It contains important information.
■ store at 20-25°C (68-77°F)
Inactive ingredients carmine, corn starch, FD&C blue no. 2, FD&C blue no. 2 aluminum lake, FD&C red no. 3, FD&C red no. 40, ferric oxide, gelatin, glyceryl monostearate, hydroxypropyl cellulose, hypromellose, magnesium stearate, methacrylic acid copolymer, pharmaceutical ink, polysorbate 80, sucrose, talc, titanium dioxide, triethyl citrate
Questions or comments? call toll-free weekdays 9 AM to 5 PM EST at 1-866-226-1680
Nexium 24HR
Clinically Proven to Treat Frequent Heartburn
Clear Minis
Tips for Managing Heartburn
• Avoid foods or drinks that are more likely to cause heartburn, such as rich, spicy, fatty and fried foods, chocolate, caffeine, alcohol and even some acidic fruits and vegetables.
• Eat slowly and do not eat big meals.
• Do not eat late at night or just before bedtime.
• Do not lie flat or bend over soon after eating.
• Raise the head of your bed.
• Wear loose-fitting clothing around your stomach.
• If you are overweight, lose weight.
• If you smoke, quit smoking.
See new warning information
NDC 0573-2452-42
Treats Frequent Heartburn
Nexium esomeprazole magnesium delayed-release capsules 20 mg/acid reducer 24HR
Nexium esomeprazole magnesium delayed-release capsules 20 mg/acid reducer 24HR
Marketed by:
Pfizer, Madison, NJ 07940 USA
© 2019 Pfizer Inc.
Made in France
For most recent product information, visit www.Nexium24HR.com
Nexium is a registered trademark of Astra/zeneca AB and is used under license.
Clear Minis
May take 1 to 4 days for full effect
42 CAPSULES
Three 14-day courses of treatment
3 BOTTLES INSIDE
Treats Frequent Heartburn
Nexium 24HR
14 Capsules Clear Minis
ACTUAL SIZE
Do Not Use if seal under bottle cap imprinted with "SEALED for YOUR PROTECTION" or yellow band around the center of each capsule is broken or missing.


Do Not Use if seal under bottle cap imprinted with "SEALED for YOUR PROTECTION" or yellow band around the center of each capsule is broken or missing.
Marketed by:
Pfizer, Madison, NJ 07940 USA
© 2014 Pfizer Inc.
Made in France
For most recent product information, visit www.Nexium24HR.com
PAA048364
Treats Frequent Heartburn
Nexium (esomeprazole magnesium) Delayed-Release Capsules 22.3 mg/Acid Reducer 24HR
May take 1 to 4 days for full effect
14 CAPSULES
One 14-day course of treatment
KEEP CARTON FOR COMPLETE WARNINGS AND IMPORTANT INFORMATION.
LIFT HERE For More Information

Stop use and ask a doctor if ■ your heartburn continues or worsens ■ you need to take this product for more than 14 days ■ you need to take more than 1 course of treatment every 4 months ■ you get diarrhea ■ you develop a rash or joint pain

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Directions ■ adults 18 years of age and older ■ this product is to be used once a day (every 24 hours), every day for 14 days ■ may take 1 to 4 days for full effect

14-Day Course of Treatment ■ swallow 1 capsule with a glass of water before eating in the morning ■ take every day for 14 days ■ do not take more than 1 capsule a day ■ swallow whole. Do not crush or chew capsules. ■ do not use for more than 14 days unless directed by your doctor

Repeated 14-Day Courses (if needed) ■ you may repeat a 14-day course every 4 months ■ **do not take for more than 14 days or more often than every 4 months unless directed by a doctor** ■ children under 18 years of age: ask a doctor before use. Heartburn in children may sometimes be caused by a serious condition.

Other Information ■ read the directions and warnings before use ■ keep the carton. It contains important information. ■ store at 20-25°C (68-77°F)

Questions or comments? call toll-free weekdays 9 AM to 5 PM EST at **1-866-226-1600**

Active ingredient (in each capsule) ***Purpose***

Esomeprazole 20 mg ..... Acid reducer

(Each delayed-release capsule corresponds to 22 3 mg esomeprazole magnesium trihydrate)

Uses ■ treats frequent heartburn (occurs **2 or more** days a week) ■ not intended for immediate relief of heartburn; this drug may take 1 to 4 days for fu l effect

Warnings

Allergy alert: Do not use if you are allergic to esomeprazole

Do not use if you have: ■ trouble or pain swallowing food, vomiting with blood, or bloody or black stools ■ heartburn with **lightheadedness, sweating or dizziness** ■ chest pain or shoulder pain with shortness of breath; sweating; pain spreading to arms, neck or shoulders; or lightheadedness ■ frequent **chest pain.** These may be signs of a serious condition. See your doctor.

Ask a doctor before use if you have ■ had heartburn over 3 months. This may be a sign of a more serious condition. ■ frequent wheezing, particularly with heartburn ■ unexplained weight loss ■ nausea or vom ting ■ stomach pain

Ask a doctor or pharmacist before use if you are ■ taking a prescription drug. Acid reducers may interact with certain prescription drugs.

3.1.2 RX PRESCRIBING INFORMATION, PATIENT LABELING, & DRUG FACTS LABELING (OTC)

Reviewer Assessment:

Was labeling submitted in this supplement? **YES**
Are the Prescribing Information or Drug Facts Labeling (OTC) contained in the submission the same as the review model labeling (not including allowable differences under 21 CFR 314.94(a)(8))? **YES**
Is the Prescribing Information shared by other ANDAs? **NO** (If yes please list ANDA numbers).
Are the specific requirements for format met under 21 CFR 201.57 (new), or 201.80 (old), or 201.66 (OTC)? **YES**

Comment: The following were deemed acceptable per the original review:

1) When asked to include an asterisk after the expression of strength and before "Each delayed release capsule…" statement, the applicant declined because the RLD does not have this.
2) When requested to add the days of the week and times of the day when a person is available to respond to questions, Perrigo elected to use the standardized format as they considered this optional information per 21 CFR 201.66(c)(9).
3) Perrigo retained the name "sugar spheres" (instead of [redacted] (b) (4) in the inactive ingredient section as it is the name listed in the NF monograph and aligns with the raw material name as it is procured by Perrigo and to maintain consistency within their excipient tracking system.

3.1.3 DESCRIPTION, HOW SUPPLIED, MANUFACTURED, DISTRIBUTED, AND/OR PACKED BY STATEMENT

[For OTC products, please include the inactives in Table 8; package sizes being marketed in Table 9; and drug product manufacturer/distributor/packer statement in Table 10.]

Reviewer Assessment:

Are there changes to the inactives in the DESCRIPTION section or OTC labeling? **YES**
Are there changes to the dosage form description(s) or package size(s) in HOW SUPPLIED section or OTC package sizes? **NO**
Are there changes to the manufacturer/distributor/packer statements? **NO**
If yes, then comment below in Tables 8, 9, and 10.

Table 8: Comparison of DESCRIPTION Section or Inactive Ingredients Subsection (OTC)

Previous Labeling Review	Currently Proposed	Assessment
FD&C blue no. 1, FD&C red no. 3, ferric oxide, gelatin, glyceryl monostearate, hypromellose, magnesium stearate, meglumine, methacrylic acid copolymer, polyethylene glycol, polysorbate 80, shellac, sodium lauryl sulfate, sugar spheres, talc, titanium dioxide, triethyl citrate	FD&C blue no. 1, FD&C blue no. 1 aluminum lake, FD&C red no. 3, ferric oxide, gelatin, glyceryl monostearate, hypromellose, magnesium stearate, meglumine, methacrylic acid and ethyl acrylate copolymer dispersion, polyethylene glycol, polysorbate 80, shellac, sodium lauryl sulfate, sugar spheres, talc, titanium dioxide, triethyl citrate	**Per S-006 drug product review, the applicant proposed for the addition of an** [redacted] (b) (4) [redacted] (b) (4) **the sponsor added non-functional colorant (FD&C Blue #1)** [redacted] (b) (4) **.** **Methacrylic acid copolymer and methacrylic acid and ethyl acrylate copolymer** [redacted] (b) (4) **are synonymous per the FDA Substance Registration System.**

Table 9: Comparison of HOW SUPPLIED Section or Packaging Sizes for OTC Products		
Previous Labeling Review	**Currently Proposed**	**Assessment**
An oblong shaped two-piece, hard gelatin capsule containing cream colored, spherical beads. (b) (4) (b) (4) (b) (4) The capsule consists of an opaque light blue body and cap. The capsule is sealed with a blue band. The band appears to be a dark blue on the body and cap. The logo "L898" is printed in black around the circumference of the cap.	**10/15/19 AR:** An oblong shaped two-piece hard shell gelatin capsule containing cream colored, spherical beads. The capsule consists of an opaque light blue body and cap. The capsule is sealed with a blue band. The band appears to be dark blue on the body and cap. The logo "L898" is printed in black around the circumference of the cap.	**Editorial changes: Acceptable**

Table 10: Manufacturer/Distributor/Packer Statements		
Previous Labeling Review	**Currently Proposed**	**Assessment**
Distributed by Perrigo Allegan, MI 49010	Distributed By Perrigo Allegan, MI 49010	**No changes: Acceptable**

4. SPECIAL CONSIDERATIONS

Please include other information that may pertain to your drug product application.

Sarah Nguyen

Digitally signed by Sarah Nguyen
Date: 1/21/2020 12:38:38PM
GUID: 508da70900028cec38f523655fb8cb64

Ellen Koo

Digitally signed by Ellen Koo
Date: 1/21/2020 12:36:02PM
GUID: 508da73d0002b687dfbf9b3859d80789